Retatrutide
An investigational triple-receptor agonist currently in clinical trials; not FDA-approved.
What it is
Retatrutide is an investigational 'triple agonist' — it targets GLP-1, GIP and glucagon receptors. It is not FDA-approved for anything; it is in late-stage clinical trials.
Phase 2 results published in 2023 reported large average weight reductions, which set the internet on fire and put retatrutide vials on gray-market sites long before any regulator has finished judging it. The honest position: promising published data, incomplete safety picture, no approved product — and anything sold as retatrutide today is by definition not a pharmaceutical product.
What researchers have actually studied it for
Obesity and metabolic disease in ongoing phase 2 and phase 3 clinical trials; no approved indication yet.
How it works
Three receptors, one molecule: the GLP-1 and GIP arms work the incretin pathways of its predecessors, while the added glucagon-receptor activity is believed to raise energy expenditure and act on the liver. The glucagon arm is the novel bet — and the source of effects trials are watching closely, including heart-rate increases.
The molecule itself
A single peptide engineered for three receptors — GIP, GLP-1 and glucagon — with the class's signature fatty-acid albumin anchor for weekly dosing. The glucagon arm is the novel chemistry: deliberately harnessing a receptor drug design previously avoided, for its energy-expenditure and liver effects.
Where it came from
Retatrutide is Eli Lilly's next step past tirzepatide, applying the same engineering lineage to a third receptor. Its phase 2 obesity data, published in the New England Journal of Medicine in 2023, reported average weight reductions around 24% at the top dose over 48 weeks — the largest yet seen for a drug candidate — sending it into a broad phase 3 program.
The timeline
2018
Preclinical triple-agonist program emerges from Lilly's incretin engineering line.
2023
Phase 2 obesity results published in NEJM: ~24% average reduction at 48 weeks — the largest reported for any candidate.
2023–24
Gray-market 'reta' vials proliferate on trial headlines.
2024–26
Phase 3 TRIUMPH program runs across obesity, diabetes, OSA and osteoarthritis populations.
What the research record actually contains
- Phase 2 obesity trial (NEJM 2023): ~24% average weight reduction at the highest dose over 48 weeks.
- Phase 2 diabetes and fatty-liver readouts with encouraging metabolic signals.
- Phase 3 TRIUMPH program ongoing — the trials that will define approval, dosing and the real safety profile.
- No published long-term safety data; heart-rate effects observed in phase 2 remain under study.
What could change this assessment
Everything hangs on TRIUMPH: total efficacy, heart-rate findings over full duration, lean-mass data and the liver-fat thread. Approval, if it comes, arrives with a label and monitoring shaped by exactly the questions the gray market currently ignores.
What's known about risks
Interim at best. Phase 2 reported the class GI effects plus dose-related heart-rate increases; the long-term meaning of chronic glucagon-receptor activation is precisely what phase 3 exists to establish. An unfinished safety story is the honest description — and gray-market vials add unverified contents on top of it.
Where it stands legally
No approval anywhere, so no lawful retail channel exists. It cannot be lawfully compounded, prescribed or sold for human use; trial participation is the only legitimate access. 'Research use only' listings are legal posture, not permission.
Worth asking a licensed provider
- 1.If I'm interested in what retatrutide represents, do I qualify for an approved alternative today?
- 2.Is there a legitimate clinical trial I could actually enroll in?
- 3.What would make waiting for approval the wrong call for my situation?
Common claims, corrected
“It's the strongest one, just not released yet.”
Reality: Phase 2 averages can't be ranked against approved drugs' phase 3 data — different populations, durations and controls. The head-to-head that would settle it hasn't been run.
“Research-use vials are early access.”
Reality: No reference standard exists outside the sponsor's labs; online vials are unverifiable chemicals wearing a trial compound's name.
Retatrutide FAQ
Is retatrutide FDA-approved?
No. It is an investigational compound in clinical trials. There is no approved retatrutide product, which means there is no lawful retail source of it either.
What makes retatrutide different from semaglutide and tirzepatide?
Receptor count: semaglutide activates one incretin receptor, tirzepatide two, retatrutide three (adding glucagon). Whether the third receptor translates into better real-world outcomes is exactly what the ongoing trials exist to establish.
Can you buy retatrutide legally?
There is no approved product to buy. Vials sold online as 'research use only' sit outside pharmacy regulation entirely — no verified contents, no oversight, no lawful pathway for human use.
What does the glucagon receptor add?
In theory, raised energy expenditure and direct liver effects — phase 2's striking liver-fat reductions are the supporting signal. It also raises heart rate, which trials are watching closely.
Is retatrutide stronger than tirzepatide?
Unknown — no head-to-head exists and cross-phase comparisons mislead. Its phase 2 numbers were larger than tirzepatide's phase 3 numbers, which is a weaker statement than it sounds.